Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
With his brother Marty, he released a string of zany children’s programs. Some became cult favorites (even among adults) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results